Navigation Links
Yongye International Announces First Quarter 2013 Financial Results
Date:5/10/2013

provided a detailed written response to NASDAQ's request for certain information relating to the Company's delay in filing its Annual Report on Form 10-K with the Securities and Exchange Commission, the collection of accounts receivable as of year-end 2012, the current state of the Company's auditor's work in connection with the financial statements to be included in the Company's Form 10-K for the fiscal year ended December 31, 2012, and the status of the Company's proposed "going private" transaction.

Subsequent to the Company's initial response, NASDAQ requested certain additional information from the Company. The Company is in regular contact with NASDAQ with respect to this matter and is working diligently to address NASDAQ's requests. The Company expects that trading in its securities will remain halted while NASDAQ conducts its inquiry and that such trading will resume only upon NASDAQ being fully satisfied with the additional information provided. 

Update on Going-Private Proposal

On April 1, 2013, the Buyer Parties confirmed to the Special Committee that they remain interested in pursuing the proposed going private transaction set forth in their proposal. On the same day, the Special Committee was provided an amended and restated financing commitment letter issued by Abax to Full Alliance, which would terminate on April 15, 2013 if the common stock of the Company had not resumed trading on NASDAQ. On April 16, 2013 the Special Committee of the board of directors was provided a letter amending the amended and restated financing commitment letter issued by Abax to Full Alliance International Limited on April 1, 2013. Pursuant to the Amendment, the Commitment Letter was amended to (i) include an additional condition precedent that the common stock of the Company has resumed trading on NASDAQ, but without any requirement that the resumption must occur by a specified date, and (ii) extend the expiration of the commitment to the
'/>"/>

SOURCE Yongye International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Yongye International to Report First Quarter 2013 Financial Results on May 10, 2013
2. Yongye International Announces Second Quarter 2012 Financial Results
3. Yongye International to Report Second Quarter 2012 Financial Results on August 9, 2012
4. Dr. Szczepan Baran will be Presenting at the International Microsurgical Simulation Society at Columbia University in New York
5. Dyadic International To Announce First Quarter 2013 Financial Results And Host Conference Call On Wednesday, May 15, 2013
6. Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"
7. Lisa Lorraine Reyes Muñoz, GeneCell International’s Physician Relation's Manager Launches Educational Meetings for General Public on Umbilical Cord Blood Stem Cells
8. Danai Brooks Joins Dyadic International as Chief Operating Officer
9. PAREXEL International Announces Acquisition of HERON Group LTD, A Leading Commercialization Consultancy
10. PAREXEL International Reports Third Quarter Fiscal Year 2013 Results
11. GeneCell International Gives Back to the Community by Participating in Local Elementary School’s Career Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s resolutions ... care of my furry companion." Nowadays there are pet salons, dog ... to take the little canine or feline darlings along wherever mommy ... some pricey toys at the pet store. But anyone who has ...
(Date:1/14/2014)... DIEGO and BETHESDA, Md. ... are joining together with two institutes from the National ... reliable tools for bringing safer, more effective treatments to ... the National Center for Advancing Translational Sciences (NCATS) and ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
(Date:1/14/2014)... 13, 2014 Bob Hainsey, a semiconductor ... 20 years in the industry, has joined SPIE, ... will serve as the society’s Science and Technology Strategist. ... SPIE as our Technology Strategist, further strengthening the technical ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... May 24 SyntheMed, Inc. (OTC Bulletin ... and commercialization of anti-adhesion products, today announced that REPEL-GYN™, ... of adhesions following gynecologic surgery, has received CE Mark ... signifies that REPEL-GYN has met the essential requirements of ...
... Mass. , May 24 Repligen Corporation (Nasdaq: ... Products Development of the Food and Drug Administration (FDA) has ... 3 (HDAC-3) inhibitor for the treatment of Friedreich,s ataxia.  Orphan ... exclusivity in the United States if the company ...
... CARLSBAD, Calif. ; May 24 MO ... microbial nucleic acid purification, announces the launch of a ... for powerful, fast and reliable homogenization and lysis of ... researchers to prepare samples for analysis faster, minimize cross-contamination, ...
Cached Biology Technology:SyntheMed Receives CE Mark Approval for REPEL-GYN™ 2Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia 2Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia 3Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia 4MO BIO Laboratories, Inc. Launches PowerLyzer(TM) 24 Bench Top Bead-Based Homogenizer 2
(Date:4/17/2014)... Singh Thursday as a "Champion of Change" for ... in the residential, commercial and industrial sectors. , ... and Computer Engineering and director of Clemson,s Center ... leading the charge across the country to create ... driving policy changes at the local level to ...
(Date:4/17/2014)... in France have hit on a novel method ... the correct and most effective treatment possible., Kidney ... western and developing world. If left untreated, apart ... renal failure and other complications. In many patients ... Clearly a more effective pathological approach to diagnosis ...
(Date:4/17/2014)... BLOOMINGTON, Ind. -- Indiana University researchers have detected new ... with diabetes. This discovery could have far-reaching implications for ... the care of over 25 million Americans. , "We ... the retinas at such early stages," said Ann Elsner, ... Optometry and lead author of the study. "We set ...
Breaking Biology News(10 mins):White House honors Clemson professor as 'Champion of Change' for solar deployment 2New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3
... Energy,s Savannah River National Laboratory and the Chernobyl Center,s ... issue of the Health Physics Journal entitled, ... Zone 25 Years After the Accident," (Vol. 101, ... Office of Environmental Management,s (EM) International Program, SRNL and ...
... Energy Department,s laboratories are making headway on two projects ... charges faster, lasts longer, runs more safely, and might ... Lithium batteries are used in a variety of everyday ... battery could also significantly increase the charge capacity of ...
... named 13 U.S. Department of Energy (DOE) researchers as ... and Engineers (PECASE). This is the highest honor bestowed ... who are early in their independent research careers. The ... a variety of fields - from research to help ...
Cached Biology News:Journal focuses on Savannah River National Labratory, Chernobyl Laboratory collaboration 2Journal focuses on Savannah River National Labratory, Chernobyl Laboratory collaboration 3National labs leading charge on building better batteries 2US Department of Energy PECASE recipients 2US Department of Energy PECASE recipients 3US Department of Energy PECASE recipients 4
... MBPK Antibody - Red, 20X ... containing MBPK antibody at 20X concentration ... fluorescence polarization assays. ... KinEASE™ 645nm FarRed fluorescence polarization assays. ...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
CD69/CD3 50 tests...
Biology Products: